Literature DB >> 26409721

Endovascular Modalities for the Treatment of Cavernous Sinus Arteriovenous Fistulas: A Single-Center Experience.

Tamer Hassan1, Sherif Rashad2, Waseem Aziz2, Ahmed Sultan2, Tamer Ibrahim2.   

Abstract

BACKGROUND: Cavernous sinus (CS) fistulas are classified into traumatic and spontaneous. Traumatic carotid-cavernous fistulas (CCFs) are usually direct internal carotid artery (ICA) high-flow fistulas; whereas spontaneous CCFs are usually dural, low-flow fistulas and generally possess less severe symptoms than direct carotid-cavernous fistulas.
METHODS: This study involved 34 patients who were classified into 2 groups: Group A included 26 patients with direct carotid-cavernous fistula; and Group B included 8 patients with indirect dural cavernous fistula. All patients had ocular manifestations. One patient had subarachnoid hemorrhage. Coils were used alone in 19 cases of direct fistula and in 1 case of dural fistulas. Coils and Onyx (Covidien, Mansfield, MA, USA) were used in 7 cases of direct fistula and in 2 cases of dural fistulas. Onyx alone was used to treat 5 cases with dural fistulas but none of the cases with direct fistulas. Covered stents and coils were used in 2 cases of direct fistulas.
RESULTS: All patients in both groups showed full recovery of their clinical signs and symptoms. Only 1 procedure-related complication was observed (3%) in which a patient had an embolic event and trigeminal dysesthesia as a result of Onyx reflux through external carotid artery-ICA anastomosis.
CONCLUSION: Coils are superior solid embolic agents used for the treatment of direct high-flow fistulas, while Onyx is more valuable in dural low-flow CCF. Onyx shortens the procedure time and decreases procedure cost. Onyx injection inside the CS proper through the transarterial or transvenous route may be safer than Onyx injected inside dural arteries supplying the CS. However, more cases are needed to determine this.
Copyright © 2015 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carotid–cavernous fistula; Onyx; cavernous sinus; coil; covered stent; exophthalmos

Mesh:

Year:  2015        PMID: 26409721     DOI: 10.1016/j.jstrokecerebrovasdis.2015.08.016

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  6 in total

1.  Comparison of polyvinyl alcohol copolymer with detachable balloons for the embolisation of direct carotid cavernous fistula: a single-centre experience.

Authors:  Xuying He; Chuanzhi Duan; Lingfeng Lai; Xin Zhang; Zhenjun Li; Xifeng Li; Tielin Li
Journal:  Eur Radiol       Date:  2017-05-08       Impact factor: 5.315

2.  Neuro-Endovascular Intervention in Traumatic Carotico-Cavernous Fistulae: A Single-Center Experience.

Authors:  Muhamad Thohar Arifin; Mohammad Ali Akbar; Widianto Illyasa; Krisna Tsaniadi Prihastomo
Journal:  Int J Gen Med       Date:  2020-10-21

3.  Development of syndrome of inappropriate antidiuretic hormone secretion (SIADH) after Onyx embolisation of a cavernous carotid fistula.

Authors:  Tsinsue Chen; M Yashar S Kalani; Andrew F Ducruet; Felipe C Albuquerque; Cameron G McDougall
Journal:  BMJ Case Rep       Date:  2016-03-21

4.  Transvenous Onyx Embolization of Carotid-Cavernous Fistulas: Mid- and Long-Term Outcomes.

Authors:  André Beer-Furlan; Krishna C Joshi; Bledi Brahimaj; Demetrius K Lopes
Journal:  J Neurol Surg B Skull Base       Date:  2020-05-15

5.  Case Report: Management of Traumatic Carotid-Cavernous Fistulas in the Acute Setting of Penetrating Brain Injury.

Authors:  Andrea Loggini; Tareq Kass-Hout; Issam A Awad; Faten El Ammar; Christopher L Kramer; Fernando D Goldenberg; Christos Lazaridis; Ali Mansour
Journal:  Front Neurol       Date:  2022-02-11       Impact factor: 4.003

Review 6.  Endovascular treatment of the cavernous sinus dural arteriovenous fistula: current status and considerations.

Authors:  Kun Hou; Guichen Li; Tengfei Luan; Kan Xu; Jinlu Yu
Journal:  Int J Med Sci       Date:  2020-05-01       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.